METHOD OF TREATING CENTRAL SUBRETINAL HEMORRHAGES Russian patent published in 2011 - IPC A61F9/00 A61K39/395 A61K38/49 A61K33/04 A61P27/00 A61M37/00 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to ophthalmology, and deals with treatment of hemorrhages which occur, for instance, at the background of age-related macular degeneration with subretinal neovascularisation. For this purpose courses of treatment are carried out in sessions, each of courses includes carrying out mydriasis of affected eye, puncture of sclera to vitreous body and alternate introduction of medications. At the first session introduced is medication which inhibits factor of vessel growth (MIFVG), fibrinolytic medication (FM) and medication of expanding gas (MEG), for instance, sulfur hexafluoride. At the second session, in case of hemorrhage, the same medications are introduced. If there is no hemorrhage at the second and following sessions only MIFVG is introduced. Simultaneously with puncture of sclera paracentesis of cornea is performed through which drainage of moisture, normalising intraocular pressure, is carried out. MIFVG dose is calculated depending on degree of retina edema, FM and MEG doses are selected proportionally to hemorrhage value determined during fundus examination. Single MEG dose constitutes 0.05-0.35 ml. After sessions, at which MEG is introduced for 1-1.5 weeks control over resolution process is performed and it is recommended to patient to preserve "face down" head position until gas is resolved completely. 10-15 seconds after introduction of all included into particular treatment session medications, needle is removed, interval between sessions is selected equal from 3 weeks to 1.5 months.

EFFECT: method increases treatment quality due to elaboration of specific regimen of impact of said treatment methods, which ensures not only elimination of hemorrhage but also leads to elimination of it causes with minimisation of traumatic factors of treatment.

3 ex